---
title: "Yixintang Pharmaceutical Co., Ltd. (002727.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002727.SZ.md"
symbol: "002727.SZ"
name: "Yixintang Pharmaceutical Co., Ltd."
industry: "Drug Retail"
datetime: "2026-05-20T08:50:42.270Z"
locales:
  - [en](https://longbridge.com/en/quote/002727.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002727.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002727.SZ.md)
---

# Yixintang Pharmaceutical Co., Ltd. (002727.SZ)

## Company Overview

Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business. The company is involved in the wholesale, retail, leasing, and operation of medical devices; sale of food, disinfectants, disinfection equipment, sanitary products and disposable medical products, household appliances, adult toys, agricultural and sideline products, cosmetics, and daily sundries and necessities; manufacturing of glasses; provision of value-added telecommunications, Internet live broadcast technology, and Internet information services for medicines, as well as clinic and foot bath services; operation of aquatic wild animals and call center; retail of publications; and decoction services for Chinese herbal medicines. It also engages in the agency sale of single-purpose commercial prepaid cards and China sports lottery; and maternal and child care activities. In addition, the company provides health care, housekeeping, amusement park, residents' daily life, and health consulting service, as well as business agency, ticket agency, personal Internet live broadcast, remote health management, corporate member points management, food delivery, and road freight transportation services.

| Item | Detail |
|------|--------|
| Industry | Drug Retail |
| Exchange | CN Market |
| Website | [www.hx8886.com](https://www.hx8886.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.43)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 7 / 8 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.76% |  |
| Net Profit YoY | 764.59% |  |
| P/B Ratio | 0.97 |  |
| Dividend Ratio | 3.95% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7286140119.19 |  |
| Revenue | 17033391981.79 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.73% | C |
| Profit Margin | 1.64% | C |
| Gross Margin | 33.09% | C |
| Revenue YoY | -3.76% | D |
| Net Profit YoY | 764.59% | A |
| Total Assets YoY | -7.45% | E |
| Net Assets YoY | -0.43% | D |
| Cash Flow Margin | 665.01% | A |
| OCF YoY | -3.76% | D |
| Turnover | 1.04 | A |
| Gearing Ratio | 51.32% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Yixintang Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.76%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "764.59%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.97",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.95%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7286140119.19",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "17033391981.79",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.73%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "1.64%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "33.09%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-3.76%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "764.59%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.45%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.43%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "665.01%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-3.76%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.04",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "51.32%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.05 | 5/8 | 274.40 | 90.80 | 83.73 |
| PB | 0.97 | 1/8 | 1.19 | 1.10 | 1.03 |
| PS (TTM) | 0.43 | 2/8 | 0.50 | 0.46 | 0.44 |
| Dividend Yield | 3.95% | 2/8 | 3.80% | 3.53% | 1.96% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Yifeng Pharmacy (603939.SH) | B | C | B | C | C | B |
| 02 | DSL (603233.SH) | B | C | A | D | B | B |
| 03 | Huaren Health (301408.SZ) | B | B | A | D | A | B |
| 04 | SYPM (301017.SZ) | C | B | A | E | A | B |
| 05 | NO.1 PHARMACY (600833.SH) | C | C | A | C | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 40% |
| Overweight | 1 | 20% |
| Hold | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.11 |
| Highest Target | 17.75 |
| Lowest Target | 13.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002727.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002727.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002727.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002727.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**